Ligand Expects 2026 Adjusted EPS of $9.50-$9.75
Ligand Pharmaceuticals expects 2026 adjusted EPS of $9.50-$9.75, versus a FactSet estimate of $9.35.
Related stories
Dis-Chem Pharmacies Reports Revenue Up 8.0% for Six Months to Aug. 31
M impact | EARNINGS | Oct 29, 2026, 04:39 PM UTC
Pharma Mar reports nine-month net income of EUR 8.7 million
L impact | EARNINGS | Oct 29, 2026, 04:39 PM UTC
Global Dominion reports nine-month EBITDA of €94.6 million
L impact | EARNINGS | Oct 29, 2026, 04:39 PM UTC
Dominion Reports Higher Nine-Month Profit and Lower Revenue
Dominion reported that net profit rose and revenue declined in the first nine months of 2026.
M impact | EARNINGS | Oct 29, 2026, 04:39 PM UTC
Air China Reports RMB 2.015 Billion Net Loss for First Nine Months
Air China reported a net loss attributable to shareholders of RMB 2.015 billion for the first nine months of 2026, reversing a profit in the year-earlier period despite higher oper
M impact | EARNINGS | Oct 29, 2026, 04:38 PM UTC
Sprouts Farmers Market fällt nach Senkung der Umsatzwachstumsprognose
Sprouts Farmers Market hat seine Prognose für das jährliche Umsatzwachstum gesenkt; die Aktie gibt nach.
M impact | EARNINGS | Oct 29, 2026, 04:37 PM UTC